Back-to-back quarters of operating profit show the company is converting revenue growth into cash, a milestone that matters for debt covenants and financial sustainability.
By The Motley Fool Team –
Key Points
-
Phathom reported third-quarter net revenues of $84.7 million.
-
Commercially insured patients can access VOQUEZNA for a $0 copay through BlinkRx.
-
Management reaffirmed full-year 2026 revenue guidance of $310 million to $325 million.
On its third-quarter 2026 earnings call, held on Oct. 29, 2026, Phathom (PHAT -1.91%) announced net revenues of $84.7 million for the quarter. The biopharmaceutical company is turning revenue growth into cash flow while expanding coverage for VOQUEZNA, its treatment for gastroesophageal reflux disease, or GERD.
Management shares three takeaways on how the business is executing.
1. Access First Initiatives Lower Patient Out-of-Pocket Costs
Phathom shifted its sales focus to educate physicians on prior authorization, which is health plan approval before coverage, and driving prescriptions through its partner pharmacy, BlinkRx. To boost fulfillment rates, it introduced a $0 copay offering through BlinkRx for eligible commercially insured patients.
At the end of Q3, we rolled out a $0 copay offering as part of our Access First strategy, available only through BlinkRx. We believe this new offering will encourage prescribers to use BlinkRx.
— Steve Basta, President and Chief Executive Officer
2. Consecutive Quarters of Operating Profitability Signal Financial Turning Point
Operating expenses rose slightly due to clinical trials and sales investments, but quarterly net revenue grew 71% year over year. That top-line growth allowed the company to deliver positive operating profit and generate positive cash flow for two consecutive quarters.
I am proud to report that for a second consecutive quarter, we have delivered operating profitability and generated cash from operations, ending the quarter with $184.6 million in cash and cash equivalent.
— Sanjeev Narula, Chief Financial and Business Officer
3. Management Is Actively Defending VOQUEZNA Exclusivity in Federal Court
Generic drug manufacturers filed litigation challenging the Food and Drug Administration’s decision that extended VOQUEZNA’s new chemical entity exclusivity, or statutory market protection against generic competition, through May 3, 2032. Phathom intervened in the lawsuit to protect its intellectual property.
Phathom has intervened in the litigation filed by BDR to continue to defend our statutory exclusivities. We intend to vigorously defend our position.
— Steve Basta, President and Chief Executive Officer
Looking Ahead
Commercial momentum accelerates across target prescribers as Phathom reiterates full-year 2026 revenue guidance of $310 million to $325 million. The company relies on established gastroenterology relationships and broad commercial coverage while maintaining pricing discipline.
We believe our second consecutive quarter of operating profitability represents a sustainable pattern going into Q4, including in total for full year 2026 and beyond.
— Sanjeev Narula, Chief Financial and Business Officer
Revenue growth is expected to outpace operating expenses, strengthening cash flow to satisfy debt covenants without requiring additional capital raises.
Our reps are making meaningful headway in GI offices every day, and we believe we are well-positioned to close out the year with a strong fourth quarter.
— Steve Basta, President and Chief Executive Officer
Where to invest $1,000 right now
When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor’s total average return is 794%* — a market-crushing outperformance compared to 203% for the S&P 500.
They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor.
See the stocks ›
*Stock Advisor returns as of November 18, 2026.

